Publication date: Jul 13, 2024
Notwithstanding the wealth of literature on COVID-19, studies focusing on young adults with autoimmune diseases (AD) are lacking. To determine early (within 7 days) and late (after 7 days) anti-SARS-CoV-2 vaccine-related adverse events (AEs), post-vaccine disease flares, COVID-19 severity and breakthrough infections (B-INFs) in young people with rheumatic diseases (RMDs) and non-rheumatic autoimmune diseases (nr-ADs) compared to healthy controls (HC). Data were captured through the international COVID-19 vaccination in autoimmune diseases (COVAD) 1 and 2 questionnaires. Of 20,685 complete responses, we identified 6010 from patients aged 18-35 years (1692 RMD, 400 nrADs, 3918 HC) who received up to 4 vaccine doses. BNT162b2 was the most frequently administered vaccine and prior to vaccination, 7% of people with nrAD were taking immunosuppressants (IS) versus 80% in RMDs. Early mild AEs were more frequent in RMDs (93%) and nr-ADs (92%) compared to HC (85%). The frequency of late mild AEs was 
| Concepts | Keywords |
|---|---|
| 35years | Adverse events |
| 7days | Autoimmune diseases |
| Rheumatic | COVID-19 |
| Vaccination | Vaccine |
| Wealth |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | COVID-19 |
| disease | MESH | breakthrough infections |
| disease | VO | vaccine |
| disease | MESH | autoimmune diseases |
| disease | MESH | rheumatic diseases |
| disease | VO | vaccination |
| disease | VO | frequency |
| disease | VO | COVID-19 vaccine |